Beech Tree Labs is developing innovative therapies to address critical patient conditions. The Company’s lead product is TML that adresses serious viral infections. Preliminary efforts are also being directed towards developing products for the treatment of muscular dystrophy and Parkinson’s disease.

Status of the products:

• BTL-TML for viral infections
  Recent publication showing efficacy for the treatment of recurring oral herpes.
  Recent completion of FDA-authorized trial for the treatment of COVID-19.

• MD-1 for muscular dystrophy
  Preliminary in vitro experiments have been completed and published. Early anecdotal clinical evaluation of MD-1 is underway.

• PD-A for Parkinson’s disease
  Extensive search for potential therapeutic molecules has been completed and evaluated by several in vitro assays. A small number of patients have been treated anecdotally with varying degrees of success, indicating the need for further refinement of the potential therapeutic products.